Research Alert: CFRA Maintains Hold Rating On Shares Of Becton, Dickinson And Company

-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

We lower our 12-month price target to $167 from $181, implying 12.4x our FY 27 (Sep.) EPS estimate, below BDX's historical levels (five- and 10-year forward averages of 15.2x and 16.8x, respectively). Owing to the spin-off of BDX's Biosciences and Diagnostics Solutions business, we think using a historical forward average is no longer a reasonable basis for valuing BDX and applying a discount to some of its key MedTech peers. We raise our FY 26 EPS estimate to $12.62 from $12.54 and keep our FY 27 estimate at $13.50. As anticipated, Q2 FY 26 performance was negatively impacted by pressures in the Alaris business (due to a tough comparison with a prior upgrade cycle), lower demand for vaccine-related products, and challenging market dynamics in China. These three areas represent less than 10% of total revenue, per BDX's commentary. Positively, the BioPharma Systems business signed two next-gen GLP-1 contracts with major pharma customers, supporting momentum for BDX's biologic growth platform, in our view.